Over the last two decades, my research program has been focused on antimalarial drug resistance (including P. falciparum and P. vivax parasites) along my different positions in the Institut Pasteur International Network, in Africa (Central African Republic, 2000-2004 and Madagascar, 2005-2008) or in Southeast Asia (Cambodia 2010-2017). I have conducted complementary studies in Madagascar and in Cambodia, based on molecular diagnostic strategies and field-based investigations, with the aims to improve our understanding on the epidemiological features of malaria endemicity and help policy makers to conduct elimination plans. Particularly, studies focused on epidemiologically associations between human host and susceptibility to P. vivax malaria have allowedto to demonstrate that P. vivax in Madagascar is causing blood stage infection and clinical disease in Duffy-negative individuals. In Cambodia, more recently, my research on P. falciparum drug resistance have been focused on the development of new in vitro assays to better characterize P. falciparum isolates resistant to artemisinin or to piperaquine. My major achievements have been to demonstrate that mutations in the propeller domain of a Kelch gene located on chromosome 13 (K13) and amplification of plasmepsin 2-3 genes are major determinants of artemisinin and piperaquine resistances, respectively. With my colleagues involved in the KARMA project, we have recently provided a worldwide mapping of the K13 polymorphisms.
Since September 2017, I have a new position at Institut Pasteur Paris, as the head of the Malaria Genetic and Resistance Group hosted by the Biology of Host-Parasite Interactions Unit. I have published >150 peer-review articles in international journals (http://publicationslist.org/didier.menard).
Click to view graph
Connections
Click to view timeline
Timeline
Projects
Former Teams
Publications
Download-
2021Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017-2018., Malar J 2021 Jan; 20(1): 48.
-
2020Towards harmonization of microscopy methods for malaria clinical research studies., Malar. J. 2020 Sep; 19(1): 324.
-
2020RIFINing Plasmodium-NK Cell Interaction., Trends Parasitol. 2020 Aug; (): .
-
2020Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda., Nat. Med. 2020 Aug; (): .
-
2020Knowing the enemy: genetics to track antimalarial resistance., Lancet Infect Dis 2020 Jul; (): .
-
2020Keep the quality high: the benefits of lot testing for the quality control of malaria rapid diagnostic tests., Malar. J. 2020 Jul; 19(1): 247.
-
2020Molecular assessment of kelch13 non-synonymous mutations in Plasmodium falciparum isolates from Central African Republic (2017-2019)., Malar. J. 2020 May; 19(1): 191.
-
2020Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis., PLoS Med. 2020 05; 17(5): e1003084.
-
2020WHO malaria nucleic acid amplification test external quality assessment scheme: results of distribution programmes one to three, Malar. J. 2020 Mar;19(1):129.
-
2020Significant efficacy of single low dose primaquine compared to stand alone artemisinin combination therapy in reducing gametocyte carriage in Cambodian patients with uncomplicated multidrug resistant malaria, Antimicrob. Agents Chemother. 2020 Mar;.
-
+View full list of publications